Navigation Links
ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
Date:9/4/2012

BARCELONA, Spain, September 4, 2012 /PRNewswire/ --

  • E-52862 is a potent, highly selective NCE with a novel mechanism of action (MOA; Sigma 1 Receptor (S1R) antagonism) currently being evaluated for the treatment of pain
  • Key data are outlined from three Phase I studies involving 175 male and female human subjects
  • These studies demonstrate a favourable safety, tolerability, pharmacokinetic and pharmacodynamic profile for E-52862
  • Phase II clinical trials evaluating E-52862 are ongoing

ESTEVE announces the recent publication of data from the Phase I clinical trial programme of a novel, highly potent and selective, once-daily, S1RA E-52862, developed by the ESTEVE R&D team, in the British Journal of Clinical Pharmacology[1].

     (Logo: http://photos.prnewswire.com/prnh/20120904/554843)

Mariano Sust, M.D., corresponding author, stated that "E-52862 represents a NCE with a novel, unprecedented mechanism of action for pain of different aetiologies.  We are very encouraged by these results and look forward to future findings from the E-52862 clinical trial programme in due course."

To fully validate the safety and tolerability of E-52862, ESTEVE performed a rigorous phase I programme. This publication reports results from three, Phase I studies involving 175 human subjects. E-52862 demonstrated a favourable safety and tolerability profile across a robust panel of assessments including adverse event recording following questioning and spontaneous reporting; physical examinations; vital signs measurements; laboratory safety tests (haematology, blood coagulation, biochemistry, urinalysis); multiple psychometric tests; computerized cognitive evaluations (including assessment of executive function, working memory and learning, reaction time and psychomotor functions); and thorough cardiac monitoring
'/>"/>

SOURCE ESTEVE
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ESTEVE Communicates its R&D Through a New Interactive Platform
2. Texas Medical Center, the largest concentration of medical research, educational and healthcare organizations in the world, announces the first Houston Stem Cell Summit to highlight the latest stem cell research and commercialization efforts
3. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
4. ARMGO Pharma, Inc. announces data which supports its Rycal program as a novel approach for the treatment of stress-induced cognitive disorders
5. Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Companys Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
6. Clinical Site Services, Industry Leader in Patient Enrollment Solutions, Announces New Website
7. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
8. Pinnaclife, Inc., Announces NDC, Inc., to Exclusively Distribute the New Animal Health Product Line!
9. Elsevier / Gold Standard Announces New Drug Class Overviews for Clinical Pharmacology
10. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
11. UBM Announces Partnership Agreement With Trade Organisation - SIPPO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... | RBJ today announces the firm brokered a long-term lease ... leading biopharmaceutical company, at Two Ledgemont Center in ... , president, and Brian Cohen , senior vice president, ... at 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... Boulder, CO / Rootstown, OH (PRWEB) January 22, 2015 ... sensitive detection platform, announced today that it has received AOAC-PTM ... O26, O45, O1O3, O111, O121, and O145; collectively referred to ... (E. coli) O157, at 1 colony forming unit (cfu) per ...
(Date:1/22/2015)... January 22, 2015 Controlled Substance Compliance ... which helps companies check the legal requirements around using ... to China. , As their international operations expand ... adopting software solutions built as a result of the ...
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, Inc., ... Inc. (NASDAQ: SQNM ), the leading ... for next generation noninvasive prenatal tests (NIPT). Through ... technology, called Mantis™, to advance analysis of clinically-relevant ...
Breaking Biology Technology:Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Global Compliance Service for Controlled Substances to Expand to China 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... Ltd. (Bovespa:,AGEN11), one of the largest provider of integrated ... to its,shareholders and investors that, on April 10, 2008, ... acquisition of 264,000 m3 of,biodiesel, for delivery between July ... was to ensure supply of the necessary volumes for ...
... Inc.,(Amex: SGN ) has confirmed that it has ... Executive Officer, Dr. Lowell T. Harmison, has,scheduled a webcast ... Dr. Harmison stated: "Now that Signalife has closed filing ... shipping,product, I am pleased to provide direction on new ...
... SIAL ), will hold its quarterly conference ... 23, 2008, at 11:00 a.m. Eastern Time,(10 a.m. ... by Thomson/CCBN and can be accessed at,Sigma- Aldrich,s ... webcast is also being distributed through the Thomson ...
Cached Biology Technology:Signalife Announces Webcast 2Signalife Announces Webcast 3Sigma-Aldrich Corporation 1st Quarter 2008 Earnings Conference Call 2
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric ... recent success of the Wocket™ smart wallet at CES 2015 in ... named as one of the "11 Hot Products at CES" in a ... CES So Far" by Newseveryday.com and "The top 10 gadgets from CES ...
(Date:1/22/2015)... 21, 2015  Analyst Report Issued by Small Cap IR. In ... that planet-wide, transactions at merchants on the leading payment cards ... of credit, debit, and prepaid cards reached 6.54 billion.  Eight ... fraudulent card usage in 2012, and credit and debit card ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... of the "Global Wearable Technologies Market and ... Overview, Trends and Forecast 2014-2020" report to ... are smart devices that can be worn on ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... definitely something to be said for first impressions. New ... can take just 20 seconds to detect whether a ... compassionate. The findings reinforce that healthy humans are ... in a tough situation. They also pave the way ...
... 90 percent of cancer deaths are caused by secondary tumors, ... To become mobile and break free from the original ... environment. Many cells have been implicated in this process, including ... collaborator in metastasis is platelets, the blood cells whose normal ...
... rare and neglected diseases that include potential treatments for ... that affects the central nervous system of newborns, a ... a rare lung disease. The six new projects are ... Rare and Neglected Diseases (TRND) program. "These projects ...
Cached Biology News:Is a stranger trustworthy? You'll know in 20 seconds 2MIT: Uncovering a key player in metastasis 2MIT: Uncovering a key player in metastasis 3NIH TRND program announces next round of drug development projects 2NIH TRND program announces next round of drug development projects 3NIH TRND program announces next round of drug development projects 4NIH TRND program announces next round of drug development projects 5
Recombinant Rhesus Monkey IFN-Alpha...
2,4-Dinitrophenyl hapten is conjugated to BSA (Bovine Serum Albumin) protein through lysine....
4-Hydroxy-3-iodo-5-nitrophenylacetyl hapten is conjugated to BSA protein through lysine by amide bonds....
Amino Acid Analysis is performed using ion-exchange separation of the amino acids from acid hydrolysates, followed by ninhydrin detection. Typical quantities required are 0.1 to 0.5 mg, depending on...
Biology Products: